CLRB News and Press, Cellectar Biosciences Inc. From 12/02/20

Gainers: Catabasis Pharmaceuticals (CATB) +44%, iBio (IBIO) +21%, Cellectar Biosciences (CLRB) +21%, Intec Pharma (NTEC) +18%, Sio Gene Therapies (SIOX) +18%.Losers: Ovid Therapeutics (OVID) -55%, Auris Medical (EARS) -35%, iRhythm Techno...

Why Are These Penny Stocks Gaining Attention In December 2020? As 2020 comes to a close, there are plenty of penny stocks to watch . While finding penny stocks may seem like a daunting task at first, it can be made much easier with a few simple tips. The first tip that all inve...

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the ...

Cellectar Biosciences ([[CLRB]] -0.9%) has announced interim results from Phase 1 study evaluating CLR 131 in relapsed or refractory brain tumors, specifically high grade gliomas, high risk neuroblastomas and select soft tissue sarcomas.Four dose levels (15, 30, 45 and 60mCi/m2 ) have been ev...

FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced CLR 131 has demonstrated p...

Our analysis concludes CLRB appears a worthwhile speculative investment at $1.15 per share primarily because the potential upside dramatically outweighs the risk of downside based on, among other things, the results of CLRB's Phase 2 trial (called CLOVER-1) of its CLR131 candidate therapy in p...

Intra-Cellular stock jumps as its bipolar trial delivers positive data Intra-Cellular Therapies Inc. (ITCI) announced positive top-line data from its Phase 3 clinical trial of its lead drug candidate lumateperone. The trial was designed to evaluate the potential of lumateperone as an ad...

FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CE...

Cellectar Biosciences ( CLRB +2.8% ) announced that a clinically meaningful 40% (6/15 patients) overall response rate (ORR) was observed in the CLOVER-1 Phase 2 study for CLR 131, in the subset of multiple myeloma (MM) patients, deemed triple class refractory who received ...

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that a clinically meaningful 4...